Healthcare / Diagnostics & ResearchKOSDAQ
$965.00
-40.00 (-4.10%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-20.4B · quality 63.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
23/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$38.5B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-77.7%
↓Gross Margin
8.2%
↓Debt/Equity
0.28
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+111.4%
FCF CAGR
—
FCF margin
-457.1%
FCF / Net income
1.17x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $5.12B · net income $-19.95B · FCF $-23.41B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $5.12B | $5.12B | $1.60B | $2.73B | $541.9M |
| Net Income | $-19.95B | $-19.95B | $-22.47B | $-16.32B | $-13.68B |
| EBITDA | $-17.28B | $-17.28B | $-20.06B | $-13.98B | $-11.57B |
| EPS | -529.00 | -529.00 | -608.00 | -609.00 | -287.56 |
| Gross Margin | 8.2% | 8.2% | -54.9% | 3.1% | 1.0% |
| Operating Margin | -392.0% | -392.0% | -1423.4% | -590.3% | -2884.8% |
| Net Margin | -389.6% | -389.6% | -1403.0% | -597.0% | -2524.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.28 | 0.28 | 0.58 | 0.18 | 0.93 |
| Current Ratio | 5.48 | 5.48 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-23.41B | $-23.41B | $-20.37B | $-15.49B | $-16.81B |
| Returns | |||||
| ROE | -77.7% | -77.7% | -111.4% | -38.0% | -120.0% |
| Valuation | |||||
| P/B | 1.42 | 1.42 | 6.24 | 2.67 | 18.16 |
| Growth & Yield | |||||
| Revenue Growth | 219.8% | 219.8% | -41.4% | 404.5% | — |
| EPS Growth | 13.0% | 13.0% | 0.2% | -111.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-56.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-608.00 → -529.00
Residual
-56.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.